AAPL312.47-3.75 (-1.19%) ▼|ABBV249.68+0.90 (+0.36%) ▲|ABT106.46+0.94 (+0.89%) ▲|ACN177.09-1.94 (-1.08%) ▼|ADBE255.63-1.63 (-0.63%) ▼|AMAT465.86-6.93 (-1.47%) ▼|AMD519.99+14.25 (+2.82%) ▲|AMGN392.89-0.29 (-0.07%) ▼|AMT174.71-1.02 (-0.58%) ▼|AMZN251.02-5.95 (-2.32%) ▼|AVGO361.15-7.42 (-2.01%) ▼|AXP322.16-3.94 (-1.21%) ▼|BA209.94-0.79 (-0.37%) ▼|BAC62.77+0.38 (+0.61%) ▲|BKNG172.08-8.22 (-4.56%) ▼|BLK1,079.45-15.92 (-1.45%) ▼|BMY64.41-0.29 (-0.44%) ▼|BNY162.76-0.09 (-0.06%) ▼|BRK-B506.51+0.68 (+0.13%) ▲|C137.89+1.15 (+0.84%) ▲|CAT814.02-8.46 (-1.03%) ▼|CL88.12-0.29 (-0.33%) ▼|CMCSA24.95-1.39 (-5.26%) ▼|COF212.11-1.85 (-0.86%) ▼|COP137.45+2.41 (+1.78%) ▲|COST901.32-8.86 (-0.97%) ▼|CRM249.26+0.14 (+0.05%) ▲|CSCO109.50+0.33 (+0.30%) ▲|CVS95.20-0.87 (-0.91%) ▼|CVX213.22+3.42 (+1.63%) ▲|DE674.49-6.25 (-0.92%) ▼|DHR204.83-0.40 (-0.19%) ▼|DIS104.61-0.45 (-0.43%) ▼|DUK119.88-1.36 (-1.12%) ▼|EMR151.56-0.59 (-0.39%) ▼|FDX310.38-3.75 (-1.19%) ▼|GD353.17-3.41 (-0.96%) ▼|GE323.84-11.07 (-3.31%) ▼|GEV949.41-21.90 (-2.25%) ▼|GILD146.32-0.33 (-0.22%) ▼|GM85.58-0.21 (-0.24%) ▼|GOOG326.97-8.41 (-2.51%) ▼|GOOGL329.44-8.92 (-2.64%) ▼|GS1,027.30-9.24 (-0.89%) ▼|HD311.34-2.37 (-0.75%) ▼|HON205.90-2.34 (-1.12%) ▼|IBM231.14-0.96 (-0.41%) ▼|INTC105.28+0.81 (+0.78%) ▲|INTU315.60-3.33 (-1.04%) ▼|ISRG351.24+1.08 (+0.31%) ▲|JNJ268.77-0.35 (-0.13%) ▼|JPM354.74+1.23 (+0.35%) ▲|KO87.88-0.48 (-0.54%) ▼|LIN464.75-3.64 (-0.78%) ▼|LLY1,128.30+4.39 (+0.39%) ▲|LMT527.30-8.86 (-1.65%) ▼|LOW198.55-2.25 (-1.12%) ▼|LRCX314.07-6.36 (-1.98%) ▼|MA566.33-4.56 (-0.80%) ▼|MCD253.65-2.16 (-0.84%) ▼|MDLZ61.67+0.04 (+0.06%) ▲|MDT92.55+0.16 (+0.17%) ▲|META654.35+40.87 (+6.66%) ▲|MMM165.26-2.26 (-1.35%) ▼|MO67.55-0.62 (-0.91%) ▼|MRK147.48-0.99 (-0.66%) ▼|MS215.27-0.97 (-0.45%) ▼|MSFT492.33-1.62 (-0.33%) ▼|MU1,024.73+24.47 (+2.45%) ▲|NEE82.72-1.11 (-1.32%) ▼|NFLX76.53-0.25 (-0.32%) ▼|NKE37.17-0.93 (-2.44%) ▼|NOW132.52-1.69 (-1.26%) ▼|NVDA224.25-1.49 (-0.66%) ▼|ORCL161.45-1.07 (-0.66%) ▼|PEP136.55-1.90 (-1.37%) ▼|PFE27.91+0.12 (+0.41%) ▲|PG142.84-2.74 (-1.88%) ▼|PLTR171.08+0.78 (+0.46%) ▲|PM183.74-0.99 (-0.54%) ▼|QCOM175.33+1.24 (+0.71%) ▲|RTX198.72-0.09 (-0.05%) ▼|SBUX100.09-1.92 (-1.88%) ▼|SCHW107.54+0.67 (+0.63%) ▲|SO88.25-0.75 (-0.84%) ▼|SPG207.46-2.17 (-1.04%) ▼|T24.98-0.62 (-2.42%) ▼|TMO606.72+3.70 (+0.61%) ▲|TMUS177.44-4.25 (-2.34%) ▼|TSLA369.42+1.26 (+0.34%) ▲|TXN260.57+1.65 (+0.64%) ▲|UBER71.37-1.77 (-2.41%) ▼|UNH390.37-10.47 (-2.61%) ▼|UNP285.44-3.02 (-1.05%) ▼|UPS99.78-0.70 (-0.70%) ▼|USB62.27-0.22 (-0.35%) ▼|V367.01-1.63 (-0.44%) ▼|VZ49.32-1.10 (-2.17%) ▼|WFC89.38+1.42 (+1.61%) ▲|WMT105.84-0.22 (-0.20%) ▼|XOM163.60+2.94 (+1.83%) ▲|AAPL312.47-3.75 (-1.19%) ▼|ABBV249.68+0.90 (+0.36%) ▲|ABT106.46+0.94 (+0.89%) ▲|ACN177.09-1.94 (-1.08%) ▼|ADBE255.63-1.63 (-0.63%) ▼|AMAT465.86-6.93 (-1.47%) ▼|AMD519.99+14.25 (+2.82%) ▲|AMGN392.89-0.29 (-0.07%) ▼|AMT174.71-1.02 (-0.58%) ▼|AMZN251.02-5.95 (-2.32%) ▼|AVGO361.15-7.42 (-2.01%) ▼|AXP322.16-3.94 (-1.21%) ▼|BA209.94-0.79 (-0.37%) ▼|BAC62.77+0.38 (+0.61%) ▲|BKNG172.08-8.22 (-4.56%) ▼|BLK1,079.45-15.92 (-1.45%) ▼|BMY64.41-0.29 (-0.44%) ▼|BNY162.76-0.09 (-0.06%) ▼|BRK-B506.51+0.68 (+0.13%) ▲|C137.89+1.15 (+0.84%) ▲|CAT814.02-8.46 (-1.03%) ▼|CL88.12-0.29 (-0.33%) ▼|CMCSA24.95-1.39 (-5.26%) ▼|COF212.11-1.85 (-0.86%) ▼|COP137.45+2.41 (+1.78%) ▲|COST901.32-8.86 (-0.97%) ▼|CRM249.26+0.14 (+0.05%) ▲|CSCO109.50+0.33 (+0.30%) ▲|CVS95.20-0.87 (-0.91%) ▼|CVX213.22+3.42 (+1.63%) ▲|DE674.49-6.25 (-0.92%) ▼|DHR204.83-0.40 (-0.19%) ▼|DIS104.61-0.45 (-0.43%) ▼|DUK119.88-1.36 (-1.12%) ▼|EMR151.56-0.59 (-0.39%) ▼|FDX310.38-3.75 (-1.19%) ▼|GD353.17-3.41 (-0.96%) ▼|GE323.84-11.07 (-3.31%) ▼|GEV949.41-21.90 (-2.25%) ▼|GILD146.32-0.33 (-0.22%) ▼|GM85.58-0.21 (-0.24%) ▼|GOOG326.97-8.41 (-2.51%) ▼|GOOGL329.44-8.92 (-2.64%) ▼|GS1,027.30-9.24 (-0.89%) ▼|HD311.34-2.37 (-0.75%) ▼|HON205.90-2.34 (-1.12%) ▼|IBM231.14-0.96 (-0.41%) ▼|INTC105.28+0.81 (+0.78%) ▲|INTU315.60-3.33 (-1.04%) ▼|ISRG351.24+1.08 (+0.31%) ▲|JNJ268.77-0.35 (-0.13%) ▼|JPM354.74+1.23 (+0.35%) ▲|KO87.88-0.48 (-0.54%) ▼|LIN464.75-3.64 (-0.78%) ▼|LLY1,128.30+4.39 (+0.39%) ▲|LMT527.30-8.86 (-1.65%) ▼|LOW198.55-2.25 (-1.12%) ▼|LRCX314.07-6.36 (-1.98%) ▼|MA566.33-4.56 (-0.80%) ▼|MCD253.65-2.16 (-0.84%) ▼|MDLZ61.67+0.04 (+0.06%) ▲|MDT92.55+0.16 (+0.17%) ▲|META654.35+40.87 (+6.66%) ▲|MMM165.26-2.26 (-1.35%) ▼|MO67.55-0.62 (-0.91%) ▼|MRK147.48-0.99 (-0.66%) ▼|MS215.27-0.97 (-0.45%) ▼|MSFT492.33-1.62 (-0.33%) ▼|MU1,024.73+24.47 (+2.45%) ▲|NEE82.72-1.11 (-1.32%) ▼|NFLX76.53-0.25 (-0.32%) ▼|NKE37.17-0.93 (-2.44%) ▼|NOW132.52-1.69 (-1.26%) ▼|NVDA224.25-1.49 (-0.66%) ▼|ORCL161.45-1.07 (-0.66%) ▼|PEP136.55-1.90 (-1.37%) ▼|PFE27.91+0.12 (+0.41%) ▲|PG142.84-2.74 (-1.88%) ▼|PLTR171.08+0.78 (+0.46%) ▲|PM183.74-0.99 (-0.54%) ▼|QCOM175.33+1.24 (+0.71%) ▲|RTX198.72-0.09 (-0.05%) ▼|SBUX100.09-1.92 (-1.88%) ▼|SCHW107.54+0.67 (+0.63%) ▲|SO88.25-0.75 (-0.84%) ▼|SPG207.46-2.17 (-1.04%) ▼|T24.98-0.62 (-2.42%) ▼|TMO606.72+3.70 (+0.61%) ▲|TMUS177.44-4.25 (-2.34%) ▼|TSLA369.42+1.26 (+0.34%) ▲|TXN260.57+1.65 (+0.64%) ▲|UBER71.37-1.77 (-2.41%) ▼|UNH390.37-10.47 (-2.61%) ▼|UNP285.44-3.02 (-1.05%) ▼|UPS99.78-0.70 (-0.70%) ▼|USB62.27-0.22 (-0.35%) ▼|V367.01-1.63 (-0.44%) ▼|VZ49.32-1.10 (-2.17%) ▼|WFC89.38+1.42 (+1.61%) ▲|WMT105.84-0.22 (-0.20%) ▼|XOM163.60+2.94 (+1.83%) ▲|
27.1 C
New York
Wednesday, September 9, 2026

Tag: benefits

newssourceFORcompanyinformationcontent1releasesmarket

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms

Stake Launches its Referral Code SHIMA – 200% Bonus and 5% Cashback for New Users in 2026

TORONTO, June 14, 2026 (GLOBE NEWSWIRE) -- Stake has announced the availability of its referral code SHIMA, providing eligible new users with access to a promotional package that includes a 200% welcome bonus and up to 5% cashback rewards. The offer is designed to enhance the onboarding experience for new account holders and provide additional value through ongoing promotional benefits.

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology...

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in angioedema in patients with chronic spontaneous urticaria (CSU) refractory to antihistamines. These results were sustained off-treatment, seven months after completion of barzolvolimab dosing (Week 76). The data continue to demonstrate barzolvolimab’s potential to shift the goal of CSU treatment from symptom control to disease modification and further support the ongoing Phase 3 trials of barzolvolimab in CSU.

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –

HorseWood & HorseBoost [Exclusive Report 2026] The Horse Gelatin Trick Male Enhancement Or Why Talking About Natural Vitality Supplement Horse Boost?

Discover the truth behind HorseWood & HorseBoost in this 2026 exclusive report. Learn how the Horse Gelatin Trick works, what ingredients are included, and whether this natural vitality supplement can support male performance, stamina, and confidence. 
Discover the truth behind HorseWood & HorseBoost in this 2026 exclusive report. Learn how the Horse Gelatin Trick works, what ingredients are included, and whether this natural vitality supplement can support male performance, stamina, and confidence.

Ddrops® Championed Active Childhoods and Healthy Growth at Aqua Champs League Fest 2026 Malaysia

KUALA LUMPUR, Malaysia, June 14, 2026 /PRNewswire/ -- Ddrops®, a Canadian family health and nutritional supplement brand, participated as a supporting sponsor of Aqua...

$100 No Deposit Bonus 200 Free Spins Real Money Casinos – All iGaming Experts Report Rising Demand for Free Spins Casinos

Vancouver, Canada, June 14, 2026 (GLOBE NEWSWIRE) --

$100 no deposit bonus 200 free spins real money promotions remain widely discussed as players look for practical ways to evaluate free spins casinos before making a deposit. As 50 no deposit free spins for real money bonus continue attracting players, many users are taking a closer look at promotional details and the overall value offered by no deposit bonus casinos.

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with...

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

FemiCore [Exclusive Report 2026] Femi Core Warning Why Thousands of Women Are Suddenly Talking About This Bladder Health Supplement

Discover ingredients, urinary microbiome science, benefits, and why thousands of women are discussing FemiCore in 2026. 
Discover ingredients, urinary microbiome science, benefits, and why thousands of women are discussing FemiCore in 2026.

Glacier Breeze Portable AC: Features, Performance Claims & Consumer Feedback Evaluated in 2026

Madrid, Spain, June 13, 2026 (GLOBE NEWSWIRE) -- A 2026 company-aligned overview of how the Glacier Breeze Portable AC is presented across official product materials, including its Twin Frost Jet design, evaporative cooling technology, cooling cartridge system, and key considerations for consumers before purchasing.

HeroMD 4-MAX Claims Evaluated: Why Men Searching “Most Effective 4-in-1 Erectile Dysfunction Formula” Are Comparing SURGE, PRIME and The HERO System Explained

HeroMD 4-MAX scam or legit? Compounded 4-in-1 sublingual ED formula with 10-min onset and 36-hr window reviewed.

Canada’s Largest Athletic Fundraiser Raises a Record $23.3 Million in Support of The Princess Margaret Cancer Foundation

More than 4800 cyclists set a new fundraising record to create a world free from the fear of cancer TORONTO, June 13, 2026 /CNW/...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBenefits

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers